Cargando…
Dexamethasone and potassium canrenoate alleviate hyperalgesia by competitively regulating IL‐6/JAK2/STAT3 signaling pathway during inflammatory pain in vivo and in vitro
BACKGROUND: Dexamethasone (Dexa) and potassium canrenoate (Cane) modulate nociceptive behavior via glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) by two mechanisms (genomic and nongenomic pathways). This study was designed to investigate the Dexa‐ or Cane‐mediated nongenomic and ge...
Autores principales: | Liu, Jie, Xie, Xiaolan, Qin, Kai, Xu, Le, Peng, Juxiang, Li, Xiangyu, Li, Xiongjuan, Liu, Zhiheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597488/ https://www.ncbi.nlm.nih.gov/pubmed/36301041 http://dx.doi.org/10.1002/iid3.721 |
Ejemplares similares
-
Phosphorylation at Ser 727 Increases STAT3 Interaction with PKCε Regulating Neuron–Glia Crosstalk via IL-6-Mediated Hyperalgesia In Vivo and In Vitro
por: Li, Xiongjuan, et al.
Publicado: (2022) -
Dexamethasone inhibits IL-8 via glycolysis and mitochondria-related pathway to regulate inflammatory pain
por: He, Ren, et al.
Publicado: (2023) -
Potassium canrenoate in brain-dead organ donors: a randomised controlled clinical trial protocol (CANREO-PMO)
por: Belarif, Lilia, et al.
Publicado: (2023) -
Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis—A Randomized Placebo Controlled Clinical Trial
por: Kotfis, Katarzyna, et al.
Publicado: (2022) -
Neutral Effects of Combined Treatment With GLP-1R Agonist Exenatide and MR Antagonist Potassium Canrenoate on Cardiac Function in Porcine and Murine Chronic Heart Failure Models
por: Demkes, Evelyne J., et al.
Publicado: (2021)